When was Cadent Therapeutics founded?

Cadent Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Where is Cadent Therapeutics located?

Cadent Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of Cadent Therapeutics?

Vasant Narasimhan of Cadent Therapeutics.

How many employees does Cadent Therapeutics have?

As of Dec 31, 2022, the latest employee count at Cadent Therapeutics is 13.

Is Cadent Therapeutics a funded company?

Cadent Therapeutics is a funded company, having raised a total of $63.7M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Feb 16, 2013.

When was the latest funding round of Cadent Therapeutics?

Cadent Therapeutics' latest funding was a $***** Series B round on Nov 15, 2018, with participation from 6 investors.

Where does Cadent Therapeutics rank among its competitors?

Cadent Therapeutics ranks 17th amongst 85 active competitors, of which 18 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Alto Neuroscience, which secured $120M in Mar, 2026.

Who are the top competitors of Cadent Therapeutics?

Cadent Therapeutics' top competitors include Alto Neuroscience, Enveda and Reunion Neuroscience. Among them, Alto Neuroscience secured the most recent funding round in March, 2026.

Cadent Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Cadent Therapeutics is an acquired company based in Cambridge (United States), founded in 2010. It operates as an Innovative medicines company reimagining medicine to improve and extend people’s lives. Cadent Therapeutics has raised $63.7M in funding from Atlas Venture and Cowen. The company has 85 active competitors, including 18 funded and 22 that have exited. Its top competitors include companies like Alto Neuroscience, Enveda and Reunion Neuroscience.

Company Details

Innovative medicines company reimagining medicine to improve and extend people’s lives. They focus on innovative science and digital technologies to create transformative treatments in areas of great medical need. The company invests in research and development to discover new medicines and expand access to treatments globally. Their work empowers patients, healthcare professionals, and societies in the face of serious disease. They are committed to making a positive impact through access to innovative medicines, environmental protection, and high ethical standards. They offer products and services in therapeutic areas like cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. They focus on research and development, clinical trials, and partnering. They are committed to ESG, global health, and inclusion.

Website: cadenttx.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2010

Location

Cambridge, United States

Stage

Acquired

Total Funding

$63.7M in 4 rounds

Latest Funding Round

Series B, Nov 15, 2018, $*****

Investors

Atlas Venture & 7 more

Ranked

17^th among 85 active competitors

Employee Count

13 as on Dec 31, 2022

Similar Companies

Alto Neuroscience & 113 more

Exit Details

Acquired by Novartis (Dec 17, 2020)

View Cadent Therapeutics' full profile

Cadent Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Mnemosyne Pharmaceuticals Inc CIN: 272199067 , United States, Active	Dec 31, 1999	-	4 (As on Dec 31, 2021)	-

Cadent Therapeutics got acquired by Novartis on Dec 17, 2020 at an acquisition amount of $*****.

Click here to take a look at Cadent Therapeutics's acquisition in detail

Cadent Therapeutics has raised a total funding of $63.7M over 4 rounds. Its first funding round was on Feb 16, 2013. Its latest funding round was a Series B round on Nov 15, 2018 for $*****. 6 investors participated in its latest round. Cadent Therapeutics has 8 institutional investors.

Here is the list of recent funding rounds of Cadent Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 15, 2018	9803818	Series B	7088882	1494455	9127463	3878154
Jan 06, 2015	1004579	Series A	7999803	9397153	1120180	5492513
Jul 02, 2013	8615117	Series A	5060220	3100165	8025571	Atlas Venture

Access funding benchmarks and valuations. Sign up today!

View details of Cadent Therapeutics's funding rounds and investors

Cadent Therapeutics' employee count trend

Cadent Therapeutics has 13 employees as of Dec 22. The total employee count is 46.0% lower than what it was in Dec 21. Here is Cadent Therapeutics's employee count trend over the years:

Employee count trend for Cadent Therapeutics

Uncover Cadent Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cadent Therapeutics include Alto Neuroscience, Enveda and Reunion Neuroscience. Here is the list of Top 10 competitors of Cadent Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alto Neuroscience 2019, San Francisco (United States), Public	AI-driven drug discovery platform for neurological diseases based on patients biomarkers	$145M	Commodore Capital, Alkeon Capital Management ... & 36 others	68/100
2nd	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Kinnevik, Premji Invest & 29 others	63/100
3rd	Reunion Neuroscience 2022, Toronto (Canada), Acquired	Developer of therapeutics for mental health conditions	$120M	MPM BioImpact, Novo Holdings & 5 others	62/100
4th	Supernus Pharmaceuticals 2005, Rockville (United States), Public	Innovating CNS treatments, improving lives through neurological and psychiatric solutions	-	New Enterprise Associates, Westwicke & 6 others	62/100
5th	Seaport Therapeutics 2020, Boston (United States), Series B	Developer of therapeutics to treat neuropsychiatric disorders	$325M	Sofinnova Investments, Foresite Capital & 7 others	57/100
6th	Vanda Pharmaceuticals 2003, Washington, DC (United States), Public	Developer of pharmaceutical products for treating CNS disorders	$33.5M	Domain Associates, MedImmune Ventures & 4 others	56/100
7th	HMNC Brain Health 2010, Munich (Germany), Series B	Developer of targeted therapies for depression and other neuropsychiatric disorders	$41.5M	The Jahr Group, Kompernass & 9 others	53/100
8th	Neurovance 2011, Cambridge (United States), Acquired	Drug to modulate neurochemicals to treat Attention Deficit Hyperactivity Disorder .	$53M	GBS, Novartis Venture Fund & 3 others	53/100
9th	Newleos 2009, Boston (United States), Series A	Developer of oral small molecules for neuropsychiatric conditions treatment	$93.5M	Goldman Sachs Asset Management, Arkin Holdings ... & 3 others	52/100
10th	Pasithea 2020, Miami Beach (United States), Public	Developer of treatments for psychiatric and neurological disorders	$1.46M	-	51/100
17th	Cadent Therapeutics 2010, Cambridge (United States), Acquired	Innovative medicines company reimagining medicine to improve and extend people’s lives	$63.7M	Access Industries, Cowen & 6 others	41/100